Business • 1 min read • Oct 8, 2026

Argenx to Discontinue Phase 3 UNITY Study of Efgartigimod in Sjgren's Disease

(RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. Following interim analysis, an Independent Data Monitoring Committee concluded th...

Staff Reporter Editorial Desk

3 views

🎧 Listen to Story

Click play to listen to audio edition

Argenx to Discontinue Phase 3 UNITY Study of Efgartigimod in Sjgren's Disease

The ongoing evolution of the Business environment marked another decisive turn today. (RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease. According to latest observations, participants are closely evaluating both immediate and forward-looking repercussions.

Executive Key Takeaways

Primary Signal: (RTTNews) - argenx SE (ARGX) announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjgren's disease.
Contextual Driver: Following interim analysis, an Independent Data Monitoring Committee concluded that the UNITY study is unable to meet its primary endpoint, and hence recommended to stop the study.
Strategic Outlook: Market and policy watchers anticipate critical regulatory and macroeconomic responses.

Market & Strategic Implications

Beyond immediate headlines, market participants are weighing secondary effects. The intersection of capital allocations, regulatory scrutiny, and shifting macroeconomic postures continues to elevate risk sensitivity across comparable assets and jurisdictions.

As further clarity emerges in upcoming briefings, institutional observers emphasize unit economics, policy enforcement, and counterparty exposure as primary barometers for long-term trajectory.